{
    "clinical_study": {
        "@rank": "163025", 
        "arm_group": [
            {
                "arm_group_label": "Bosentan", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Bosentan (125 mg)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single dose of placebo (125 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the effect of ET blockade on the acute exercise\n      induced blood flow and endothelial function in subjects with T2DM. We hypothesize that\n      combining ET - blockade with exercise training leads to an acute increase of exercise\n      induced blood flow when compared with exercise alone. We expect that this will lead to an\n      optimization of vascular training effect in T2DM."
        }, 
        "brief_title": "ET-blockade and Exercise Induced Blood Flow in T2DM", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 Diabetes Mellitus (>2 years since diagnosis) OR controls\n\n        Exclusion Criteria:\n\n          -  <40 years of age\n\n          -  >65 years of age\n\n          -  smoking\n\n          -  cardiovascular disease\n\n          -  diabetes related manifest vascular complications\n\n          -  Type 1 Diabetes Mellitus\n\n          -  use  of Glibenclamide\n\n          -  use of HIV drugs\n\n          -  use of calcineurin inhibitors\n\n          -  use of drugs that interfere with CYP3A4 and CYP2C19"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779596", 
            "org_study_id": "ET-EX-ACUTE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bosentan", 
                "intervention_name": "Bosentan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Bosentan", 
                    "Tracleer", 
                    "actelion pharmaceuticals", 
                    "125 mg oral dose"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Placebo", 
                    "actelion pharmaceuticals", 
                    "125 mg oral dose"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bosentan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "diabetes", 
            "endothelial function", 
            "exercise", 
            "blood flow", 
            "bosentan"
        ], 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "state": "Gelderland", 
                    "zip": "6525 EX"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of a Dual ET-blocker on Exercise Induced Blood Flow and Endothelial Function in T2DM", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "exercise induced blood flow", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779596"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "exercise induced Flow Mediated Dilation", 
            "safety_issue": "No", 
            "time_frame": "2 hours"
        }, 
        "source": "Radboud University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2010"
    }
}